Auflistung Nach Schlagwort "temozolomide"
Anzeige der Dokumente 1-10 von 10
-
Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis
(2015)Introduction: Maximizing responses of malignant gliomas is hampered by resistance to temozolomide (TMZ). Increasing efficacy but not toxicity is a key issue when testing drug combinations. The antimyeloma agent bortezomib ... -
Focus on the use of resveratrol as an adjuvant in glioblastoma therapy
(2020)Glioblastoma (GB) represents the most common and malignant form of glioma cancer. The Gold Standard in Glioblastoma is neurosurgical tumor removal and radiotherapy treatment in concomitant with temo-zolomide (TMZ). ... -
High-risk pituitary adenomas and strategies for predicting response to treatment
(2022)High-risk pituitary adenomas are aggressive. They show clinical and imaging features similar to those of carcinomas, including infiltration of the surrounding brain structures, but lack cerebrospinal or systemic metastases. ... -
Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis
(2022)Introduction: The use of immune checkpoint inhibitors (ICIs) as a front-line treatment for metastatic renal cell carcinoma (RCC) has significantly improved patient’ outcome. However, little is known about the efficacy or ... -
Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo
(2020)Glioblastoma multiforme (GBM) is the most severe primary brain cancer. Despite an aggressive treatment comprising surgical resection and radio/chemotherapy, patient's survival post diagnosis remains short. A limitation for ... -
Melanoma: The Radiotherapeutic point of view; review of the current literature
(2011)Surgery remains the mainstay of melanoma therapy at all sites. Melanoma is widely believed to be a radioresistant tumor, a misconception that has historically led to the limited use of RT for its treatment. We searched ... -
MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications
(2019)Introduction: Temozolomide (TMZ) is currently considered as a rational therapeutic option for patients with progressively aggressive pituitary adenomas and carcinomas not responding to conventional therapies. Administration ... -
Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation
(2006)Background: Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown. Patients and Methods: ... -
The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
(2020)Gliomas are the most common primary brain tumors in adults. They are generally very resistant to treatment and are therefore associated with negative outcomes. MicroRNAs (miRNAs) are small, non-coding RNA molecules that ...